M
alaria, an infectious disease transmitted to people through the bite of female Anopheles mosquitoes infected with Plasmodium falciparum or Plasmodium vivax, still afflicts millions of people, with almost 90% of cases on the African continent. Even though the number of malaria cases has fallen globally from an estimated 237 million cases in 2010 to 216 million cases in 2016, malaria still causes 445,000 deaths per year, 99% of which are due to P. falciparum in Africa (1) . Parasite resistance against currently recommended artemisinin-based combination therapies (2, 3) is a concern, and antimalarial drugs with a novel mode of action are urgently needed. We previously reported the identification of the 2-aminopyridine compound MMV390048 (also known as MMV048), which is efficacious in vivo against all measurable Plasmodium life cycle stages except hypnozoites (4) . MMV048 acts through the inhibition of Plasmodium phosphatidylinositol 4-kinase (PI4K) and is the first and sole agent with this mode of action that has entered clinical development. PI4K was reported as a target for Plasmodium in 2013 with inhibition by other compound classes (5) . The low aqueous solubility associated with MMV048 in biorelevant medium was identified as one of the issues to address in the next generation of PI4K inhibitors along with improved potency. Toward this goal, a scaffold change from the 2-aminopyridine to the 2-aminopyrazine core with concomitant introduction of aqueous solubilizing groups delivered analogues with a better developability profile with respect to improved physicochemical properties, as well as a significant improvement in potency across the parasite life cycle. Improved aqueous solubility was optimally achieved through the incorporation of a piperazinylamide group on the phenyl ring at the 5-position of the 2-aminopyrazine scaffold, leading to UCT943 (Fig. 1 ). This compound, among other attributes, showed potent in vitro activity against multiple stages of the parasite life cycle and excellent in vivo efficacy in the Plasmodium berghei and P. falciparum NSG (NOD-scid IL-2R␥ null ) mouse models (6) . In order to assess the potential of UCT943 as a follow-on compound to MMV048 and a preclinical antimalarial candidate, physicochemical, parasitological, and pharmacological profiling was undertaken. Furthermore, extensive drug metabolism and pharmacokinetics (DMPK) profiling was carried out in order to facilitate the prediction of human pharmacokinetic (PK) parameters and the efficacious single dose in humans. The results are reported here.
RESULTS AND DISCUSSION
Rationale for optimization of MMV048 resulting in UCT943. Although MMV048 showed good potency against asexual blood stage parasites, there was room for improvement with respect to activity against liver and the transmissible gametocyte stage parasites (4) .
During first-in-human (FIH) studies, MMV048 showed high variability in exposure, which was attributed to low solubility. Intensive and time-consuming formulation work had to be carried out in order to identify a new formulation with a more consistent and 3-fold greater exposure (www.mmv.org/newsroom/interviews/mmv048-0).
To avoid such developability issues in the future, improved solubility, pH dependent and in biorelevant medium, was identified as the main differentiating factor in follow-on compounds. Thus, chemical modifications to MMV048 were made in such a way as to incorporate solubility-enhancing moieties. In this regard, the methyl sulfonyl group of MMV048 was replaced by a water-solubilizing piperazinyl carboxamide on the phenyl ring at the 5-position of the 2-aminopyrazine core to deliver UCT943 (6) . Improvements in asexual blood stage and liver stage activities were achieved by replacing the 2-aminopyridine ring with a 2-aminopyrazine ring, which also maintained good potency against gametocytes (6) . One key objective of this study was first to determine if these improvements would translate into better in vivo efficacy in the P. falciparum-infected NSG mouse model and, accordingly, a low predicted human dose.
In vitro antiplasmodial activity. The biological target of the clinical candidate MMV048 was identified to be Plasmodium phosphatidylinositol 4-kinase (PI4K) through resistant-mutant generation, sequencing, and pulldown experiments (4) . Plasmodium PI4K has recently been identified as a new and promising drug target, which is present at all life cycle stages of the P. falciparum and P. vivax parasites (5). UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with a 50% inhibitory concentration (IC 50 ) of 23 nM. When tested against a 5-fold-resistant P. falciparum strain generated against MMV0489, due to a mutated pi4k (pfpi4k) locus (4), UCT943 displayed a 6-fold shift in IC 50 relative to that of the parental Dd2 strain (14 nM relative to 2.2 nM) (see Table S2 in the supplemental material). When resistance was selected for in Dd2-B2 using UCT943, pfpi4k mutants with a 4-or 9-fold IC 50 shift were obtained (Table S3 ). These mutants carried the G1309V or Y1342F mutation, respectively, located in the same region of pi4k as MMV048-selected mutations reported elsewhere (4) . Resistance selection studies indicated a minimum required inoculum of 10 7 Dd2 parasites for resistance to emerge, which is similar to that of MMV048 (4) . In comparison, IC 50 shifts were within 2-fold when UCT943 was tested against strains containing mutated loci in either pfcytB, pfdhodh, pfatp4, or pfcarl. These data indicate that UCT943 and MMV048 have the same molecular targets and that, similarly to MMV048, UCT943 is expected to have transmission-blocking and liver stage activities. Importantly, UCT943 maintained high in vitro selectivity (Ͼ200-fold) for the parasite PvPI4K versus the human PI4K␤ isozyme (IC 50 of PI4K␤, 5.4 M), inhibition of which is linked to immunosuppressive effects (7) .
UCT943 was one of the most potent compounds assessed in the 2-aminopyrazine chemical series (6) , with IC 50 s of 5.4 and 4.7 nM against NF54 and K1 P. falciparum strains, respectively, values that are 5-to 6-fold more active than the IC 50 s of the clinical candidate MMV048 (4) (Fig. 2) . In addition, UCT943 was equally active against the drug-sensitive NF54 strain and multidrug-resistant strains, with IC 50 s ranging from 4 to 7 nM, thus suggesting that cross-resistance with existing antimalarials is a low risk (Table S1 ). UCT943 primarily exhibited blood stage activity against schizonts (Table S5) , which correlates with a slow rate of kill, as determined in the in vitro parasite reduction ratio (PRR) assay (lag phase, 48 h; log PRR, 2.5 at 10ϫ the 50% effective concentration [EC 50 ] in strain 3D7) and in the in vitro speed assay (Table S5 ). As expected, the killing rate profile of UCT943 was similar to that of MMV048 (lag phase, 48 h; log PRR, 2.7) (4). When tested against P. falciparum clinical isolates of the Ivory Coast, UCT943 exhibited potent activity (2 to 15 nM) ( Table S6 ). The potency of UCT943 against clinical isolates from Papua, Indonesia, was significantly higher than that of MMV048 in P. vivax and in P. falciparum (median UCT943 IC 50 s of 14 nM and 29 nM for P. vivax and P. falciparum, respectively [P ϭ 0.012]; median MMV048 IC 50 s of 93 nM and 202 nM, respectively [P Ͻ 0.001]) ( Fig. 2 and Table S7 ). Interestingly, both compounds displayed higher potency against P. vivax than against P. falciparum, a trend that was also observed for another PI4K inhibitor, KDU691, albeit to a lesser extent (5) .
When tested against other stages of the parasite life cycle (Fig. 2) , UCT943 was 2 to 50 times more potent than MMV048 (4). UCT943 was potent against early-stage (Ͼ90% stages I to III) and late-stage (Ͼ95% stages IV and V) gametocytes (IC 50 s of 134 nM and 66 nM, respectively) and inhibited the formation of both male and female gametes (IC 50 of Ϸ80 nM) in a dual-gamete formation assay (DGFA). The latter activity translated into transmission-blocking activity (target candidate profile TCP5 as defined by Burrows et al. [8] ) in a standard membrane feeding assay (SMFA), with an IC 50 of 96 nM (9), equivalent to that of MMV048 (Fig. 2) . In-depth clinical PK/pharmacodynamic (PD) investigations would be needed to determine doses that would afford coverage for both blood stage and transmission-blocking activities. A single drug with both activities would be a valuable addition to the arsenal of antimalarial medicines. UCT943 also exhibits better in vitro liver stage activity than MMV048 (potentially addressing TCP3 and TCP4 [8] ), targeting schizonts in vitro (IC 50 s of Ͻ100 nM and Ͻ10 nM in P. vivax and Plasmodium cynomolgi, respectively, when tested prophylactically, and of 0.92 nM in P. berghei), as well as inhibiting the formation of hypnozoites (IC 50 s of Ͻ100 nM and Ͻ10 nM in P. vivax and P. cynomolgi, respectively, when tested prophylactically) (Fig. 2) . The parasitophorous vacuole membrane protein UIS4 becomes internalized in MMV048-treated P. berghei HepG2 cultures, a morphology associated with in vitro liver stage parasite clearance (4). Though UCT943 was not evaluated for such morphological changes, its activity against schizonts offers prospects for improved prophylactic liver stage activity relative to that of MMV048.
Physicochemical characterization. UCT943 was stable in the solid state over a period of 18 months and was chemically stable at 20°C in solutions of dimethyl sulfoxide (DMSO), water (pH 6.2), and buffers (pH 2 and pH 7.4) over 6 days.
The piperazinylamide group accounts for the significantly lower measured lipophilicity of UCT943 (distribution coefficient, logD, of Ϫ0.27) than that of MMV048 (logD of 2.6). This, combined with a pK a of 7.5, results in higher measured solubility in aqueous medium than that of MMV048 across a range of physiologically relevant pHs up to 6.5, where the compound is protonated ( Table 1 ). The compound was also highly soluble in simulated gastric fluid (SGF; pH 1.8), fed-state simulated intestinal fluid (FeSSIF; pH 5.0), and fasted-state simulated intestinal fluid (FaSSIF; pH 6.5) media (Ͼ1.5 mg/ml), predictive of a good dissolution in the gastrointestinal tract. The pH-dependent solubility profile of UCT943 in aqueous medium was typical of a weak base with higher solubility at pH below the pK a , i.e., 7.5 ( Fig. 3 ). UCT943 exhibited high permeability across Caco-2 cells in both directions (apparent permeability, basolateral to apical direction, P app B¡A ϭ 25 ϫ 10 Ϫ6 cm/s; P app A¡B ϭ 28 ϫ 10 Ϫ6 cm/s) without appreciable efflux (efflux ratio of 0.93) ( Table 2 ). With high FaSSIF solubility and high permeability, UCT943 can be classified as a developability classification system (DCS) class I compound, which bodes well for a much more favorable development pathway compared to that of MMV048, which was classified as DCS class II (Fig. 4) (10) . The high solubility and permeability of UCT943, along with its potent anti-Plasmodium activity against all stages of the parasite life cycle (see the section "Rationale for optimization of MMV048 resulting in UCT943"), triggered comprehensive DMPK profiling toward determining its potential for preclinical development. In vitro and in vivo metabolism studies. There was no evidence of chemical instability for UCT943 in human, dog, rat, or mouse blood or plasma. The compound was moderately bound to plasma proteins with little species differentiation (unbound fraction [f u ] in plasma, 0.10 to 0.16). It also had a greater propensity than MMV048 (blood-to-plasma partitioning ratio [B/P] of ϳ1.0 across species) to bind or distribute in red blood cells (RBCs) than in plasma (B/P varying from 1.5 to 2.3 across species). This is likely due to enhanced partitioning through the acidic phospholipid bilayer of the cell membrane due to the weakly basic piperazine moiety. The higher partitioning into RBCs possibly contributes to a small degree to its potent in vitro and in vivo antiPlasmodium activity by localizing the drug where the parasite resides.
As an indicator of hepatic metabolism, UCT943 was incubated across species with hepatocytes, liver microsomes, and liver S9 fractions ( Table 2 ). The intrinsic clearance (CL int ) of UCT943 in both microsomes and hepatocytes was low in human, rat, and mouse (CL int , Ͻ11.6 l/min/mg in microsomes and Ͻ4 l/min/10 6 cells in hepatocytes), while it was moderate in dog (CL int , 28.2 l/min/mg in microsomes and 9 l/min/10 6 cells in hepatocytes). Additionally, no significant metabolism (Ͻ10% degradation) was detected in the human liver S9 fraction, showing that enzymes other than cytochrome P450s (CYPs) were not extensively involved in the metabolism of UCT943. No measurable inhibition was detected at 20 M against any of the CYP isoforms tested (CYP2D6, CYP2C9, and CYP3A4/5), indicating that UCT943 has low potential for in vivo enzyme inhibition and that adverse drug-drug interactions through oxidative metabolism are likely to be minimal.
Metabolite identification was performed in vitro using liver microsomes and hepatocytes, as well as in vivo by analyzing the collected blood samples from mouse PK experiments (Fig. 5a) . In vitro, liver microsomes and hepatocytes gave a complementary (Fig. 5b) . UCT943 was mainly metabolized into an oxidation metabolite (Pϩ16), which was further dehydrogenated into two metabolites, Pϩ14 (I and II) in nonhuman species. Further biotransformation on the piperazine ring gave metabolites PϪ26 (piperazine ring cleavage) and Pϩ28. The formation of the carboxylic acid derivative by hydrolysis of the piperazinylamide moiety (PϪ68) was more easily detected in hepatocytes and in vivo in mice than in liver microsomes, presumably due to the higher concentration of the enzymes responsible for this particular biotransformation. The contribution of these metabolites to the activity of the parent UCT943 is under investigation. Notably, the PϪ68 metabolite, resulting from the hydrolysis of the carboxamide, showed high activity, albeit lower than that of the parent, with IC 50 s of 33 nM and 32 nM against P. falciparum NF54 and K1 strains, respectively (6). Pharmacokinetic studies. When administered intravenously, the blood clearance (CL b ) of UCT943 was low in mice, rats, and dogs (Table 3) , with a value of less than 20% of hepatic blood flow (11) , and very low in monkeys, with a blood CL of Ͻ5% of hepatic blood flow, which is consistent with the high in vitro metabolic stability. The plasma volume of distribution at steady state (V ss ) was high in all species (V ss of 7.1 to 13.1 liters/kg), suggesting that the compound extensively distributes and accumulates in organ tissues. This would be expected for a basic compound due to partitioning into cell membranes by association with acidic phospholipids (12) . As a consequence of the low CL and high V ss , half-lives (t 1/2 s) were long, ranging from 6 h in mice to 29 h in monkeys. When dosed orally in mice and dogs, UCT943 was rapidly absorbed (time of maximum concentration, T max , of Ͻ3 h), while absorption in rats and monkeys was slower, with maximum concentrations (C max s) reached after 12 h and 7 h, respectively (Fig. 6 ). Oral bioavailability was high across all species, ranging from 66% to 98%. The good oral bioavailability and the long t 1/2 of UCT943 across species are encouraging in terms of the goal of achieving a single-dose treatment and cure for malaria, which would boost patient compliance in resource-limited regions of the world, where the medical infrastructure is not sufficient. If these PK properties are confirmed in humans, UCT943 could thus be a potential combination partner in a single-exposure radical cure and prophylaxis (SERCaP) treatment, as proposed by the Medicines for Malaria Venture (MMV) (8) .
Next-Generation
In vivo efficacy studies. When dosed at 10 mg/kg per os (p.o.), UCT943 reduced parasitemia by Ͼ99.9% in the mouse P. berghei infection model and cured all mice, with Ͼ30 mean survival days (MSD). At 3 mg/kg p.o., no complete cure was achieved, and MSD was 10 days (6), albeit parasitemia was reduced by 99%. The resulting 90% effective dose (ED 90 ) was 1.0 mg/kg p.o. in the P. berghei infection model. In the P. falciparum-infected NSG mouse model (Fig. S1 ), UCT943 was 2-fold more potent than MMV048, with an ED 90 of 0.25 mg/kg for UCT943 and 0.57 mg/kg for MMV048 (4). PK data showed that the exposure of UCT943 was dose dependent (6) . As PK/PD relationships in the humanized NSG mouse model have been found to be predictive of the induced blood stage malaria (IBSM) model in human volunteers (13), we used the NSG mouse efficacy data for human dose prediction (see the next section). Prediction of human pharmacokinetics and efficacious single dose by PK/PD modeling. (i) Allometric scaling. The slope used to predict plasma CL by allometric 
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Antimicrobial Agents and Chemotherapy scaling was close to 0.75 (0.73), while the slope used to predict plasma V ss was close to 1 (0.90), as expected for metabolic processes and volumes, respectively (14) (Fig. 7) . The predicted human plasma V ss was moderately large (6.3 liters/kg), and the predicted human plasma CL was low (0.20 liters/h/kg), as shown in Table 4 . When converted using the B/P ratio of 1.5, the predicted human blood clearance was 0.10 liters/h/kg, i.e., less than 10% of liver blood flow (11) . The predicted t 1/2 in humans was 27 h which, together with a long mean residence time of 32 h, suggests that the compound will be a long-duration antimalarial agent.
(ii) Estimation of MPC in blood in the P. falciparum-infected NSG mouse model. From the PK/PD model ( Fig. S2 and S3) , the compound-specific PD parameters EC 50 and maximal kill rate constant (K kill ) were estimated to be 3.7 ng/ml and 0.060/h, respectively. The minimum parasiticidal concentration in blood (MPC b ), calculated using the EC 50 , was 7.4 ng/ml in NSG mouse blood and 5.2 ng/ml in human blood (Table 4) , after correction for P. falciparum-infected NSG mouse and human B/P partitioning data (2.8 and 1.5, respectively). The MPC in plasma (MPC p ) used for human dose prediction was therefore 2.6 ng/ml. The in vivo parasite reduction ratio (PRR) of 48 h predicted by the PK/PD model (log PRR of 1.25) correlated closely to the in vitro moderate killing profile (log PRR of 2.5), confirming UCT943 as a slow-acting antimalarial compound in this model.
(iii) Prediction of human pharmacokinetic parameters and efficacious dose. The human PK profiles modeled in the Berkeley Madonna program predicted a single human dose of 50 to 80 mg, based on dog and monkey data, respectively, in order to maintain the plasma concentrations above the predicted therapeutic level (that is, the plasma MPC of 2.6 ng/ml) for 8 days (i.e., four asexual parasite cycles) (Fig. S4 and S5 ). In this model, a single administration of the efficacious dose to maintain plasma concentrations above the MPC p for 8 days resulted in an area under the curve (AUC) of 4,213 to 8,223 ng · h/ml and a predicted C max of 234 to 358 ng/ml, based on monkey and dog, respectively. The low predicted dose is particularly encouraging since it leaves a generous margin for potential dose increases in case the predicted value is underestimated or the dose increase is deemed desirable to prevent the development of resistance or to ensure activity against other malaria species (including P. vivax) (see the section above on the rationale for optimization of MMV048). In vitro cytotoxicity, cardiotoxicity, and genotoxicity. Cytotoxicity, assessed against four mammalian cell lines, was found to be low, with a UCT943 selectivity index (SI) greater than 2,200 relative to the IC 50 in NF54 and greater than 170-fold against the highest IC 50 in P. falciparum clinical isolates ( Table 5 ). The UCT943 SI is equivalent to or greater than that of MMV048. Relative to the predicted upper unbound C max (0.13 M) for the human efficacious plasma exposure, a 90-fold margin is thereby predicted and is sufficiently high to warrant progression into in vivo preclinical toxicology studies.
The safety margins over cardiotoxicity risk were largely improved with UCT943 compared to those with MMV048 (SIs in Table 5 ). The hERG (ether-à-go-go-related gene) IC 50 of 10 M corresponds to an 80-fold margin relative to the predicted therapeutic unbound C max exposure for efficacy, which indicates a low risk of QT interval prolongation at therapeutic exposures. The margins to potential safety issues associated with potential off-target activities at other ion channels (Na V 1.5, Ca V 1.2, and K V 1.5) are even higher (Table 5) .
Genotoxicity was evaluated using the Ames and mouse micronucleus tests, in which UCT943 tested negative at the highest concentrations ( Table 5 ), suggesting that the compound does not have the potential to result in back-mutation of a defective gene to recover its function (Ames test) (15) and does not have the ability to induce the formation of micronuclei during cell division as a consequence of genetic damage (micronucleus assay) (16) .
In vivo G6PD hemolysis. In the search for new antimalarial compounds, it is essential to develop drugs which do not pose a red blood cell hemolysis risk to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (8) . When assessed for in vivo hemolytic toxicity in NOD-SCID mice engrafted with A Ϫ G6PD-deficient human red blood cells (huRBCs), UCT943 showed day 7 huRBC levels comparable to those of mice treated with the vehicle control, these levels being significantly higher than those of the positive control primaquine (25 mg/kg/day). This indicates that UCT943 does not induce hemolytic toxicity at doses of either 1.5 or 10 mg/kg/day (Fig. S6) , which is higher than the ED 90 of 0.25 mg/kg in the P. falciparum NSG model of infection. Assessment of other markers of hemolysis, including spleen weight and mouse reticu- locyte levels, also supports the finding that UCT943 did not induce hemolytic toxicity (Fig. S7a and b) .
Conclusion. UCT943 was optimized for antiplasmodial activity from a series of 2-aminopyrazines by structural modification of the clinical candidate MMV048, an inhibitor of an essential Plasmodium enzyme, PI4K. Incorporation of a piperazinylamide group resulted in enhanced water solubility while maintaining high permeability, both of which are key parameters for a good developability profile and for achieving high drug exposure. This, combined with minimal in vitro metabolism in liver subcellular fractions and in hepatocytes, translated into low clearance, sustained exposure, and high bioavailability in preclinical species. UCT943 was potent against all stages of the Plasmodium parasite life cycle, as well as against resistant P. falciparum and P. vivax clinical isolates. The 5-fold increase in in vitro antiplasmodial activity of UCT943 compared to that of MMV048 translated into excellent efficacy in the P. berghei mouse model and improved efficacy in the humanized P. falciparum mouse model. UCT943 was found to be a slow-acting, long-duration antimalarial compound, similar to quinoline antimalarials such as mefloquine. The predicted human single dose using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg, which offers considerable potential for the drug candidate. The high safety margins over cytotoxicity and cardiac toxicity highlighted here are much larger than the predicted human therapeutic exposure, which is promising. Based on the data presented, UCT943 displays asexual blood stage, transmission-blocking, and liver stage activities and thus has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) treatment of uncomplicated malaria. This breadth of activity offers considerable flexibility with respect to treatment options and target product profiles (TPPs) that might be addressed and has contributed to the selection of UCT943 for preclinical development as a follow-on compound to MMV048.
MATERIALS AND METHODS
Chemistry. UCT943 was synthesized in seven steps from commercially available 2-aminopyrazine, as previously described (6) .
In vitro antiplasmodial activity. (i) Asexual blood stage assays. (a) Cross-resistance against field isolates. UCT943 was tested using the [ 3 H]hypoxanthine incorporation assay (17, 18) against a panel of drug-sensitive and drug-resistant P. falciparum strains (see Table S1 in the supplemental material), as well as against a panel of resistant P. falciparum clones generated in the laboratory of David Fidock (Columbia University, USA) (Table S2) .
(b) In vitro P. falciparum resistance generation to UCT943 and PI4K gene sequencing. The generation of UCT943-resistant P. falciparum clones was performed as described elsewhere (4) ( Table S4) .
(c) Ex vivo assay against resistant P. falciparum clinical isolates from Côte d'Ivoire. Drug susceptibility of P. falciparum isolates from Côte d'Ivoire, West Africa, was measured using incorporation of SYBR green into the parasite's DNA as described before (19) . The drug plates contained 10 serial concentrations of the antimalarials, with a maximum concentration of 1,170 nM for UCT943.
(d) Ex vivo schizont maturation drug susceptibility assay against P. vivax and P. falciparum clinical isolates. Drug susceptibility of P. vivax and P. falciparum isolates from Papua, Indonesia, was measured using a modified schizont maturation assay as described previously (19) . The drug plates contained 11 serial concentrations of the antimalarials, with maximum concentrations of 2,993 nM for chloroquine, 1,029 nM for piperaquine, 338 nM for mefloquine, 49 nM for artesunate, and 297 nM for UCT943.
(ii) Liver stage assays. (a) P. berghei liver stage assay. Plasmodium berghei luciferase sporozoites were obtained by dissection of infected Anopheles stephensi mosquito salivary glands. A sporozoite invasion assay was performed as described in Le Manach et al. (6) using the rodent parasite P. berghei, which is able to infect human hepatocarcinoma HepG2-A16-CD81EGFP cells (20, 21) .
(b) P. cynomolgi liver stage assay. Primary rhesus hepatocytes were infected in vitro with P. cynomolgi sporozoites, and the drug assays were performed as previously reported by Zeeman et al. (22) .
(c) P. vivax liver stage assay. A P. vivax liver stage assay was implemented in human hepatocytes infected in vitro with P. vivax sporozoites, according to the protocol described in Sattabongkot et al. (23) .
(iii) Gametocyte assays. In vitro gametocytocidal activity was determined using luciferase reporter lines specifically enabling screening against early-stage gametocytes (Ͼ90% stages I to III) and late-stage gametocytes (Ͼ95% stages IV and V) as per Reader et al. (24) . Methylene blue (5 M) and MMV048 (5 M) were routinely included as controls.
(iv) P. falciparum DGFA. Transmission-blocking activity of UCT943 was assessed in a dual-gamete formation assay (DGFA), which utilizes a dual readout that individually and simultaneously reports on the functional viability of male and female mature stage V gametocytes, as per Ruecker et al. (25) .
Physicochemical properties. The pK a of UCT943 was determined by potentiometric titration as(CHO), Vero, and HepG2 cells, using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay (36, 37) .
(ii) Cardiotoxicity. UCT943 was tested for inhibition of the human ether-à-go-go-related gene (hERG) K ϩ channel (K v 11.1), human K v 1.5 K ϩ channel, and human voltage-gated sodium channel Na v 1.5 using IonWorks patch clamp electrophysiology (38) and for inhibition of the human Ca v 1.2 calcium channel (cardiac L-type) using a fluorescence Ca 2ϩ assay. For all assays, 50% cytotoxic concentrations (CC 50 s) were determined from 8-point dose-response curves generated using 3-fold serial dilutions from the maximum final assay concentration.
(iii) Genotoxicity. (a) Ames. UCT943 was assessed for mutagenic toxicity by measuring its ability to induce reverse mutations in a Salmonella enterica serovar Typhimurium-Escherichia coli/microsome plate incorporation assay (15, 39) . Maximum concentrations were 5,000 g per plate.
(b) Micronucleus. UCT943 capability to induce clastogenicity/aneugenicity in CHO-WBL cells was determined by measuring the extent of micronucleus formation with and without exogenous metabolic activation (Aroclor 1254-induced rat liver S9). The maximum concentration was 500 g/ml.
In vivo G6PD hemolysis. In vivo hemolytic toxicity was assessed in NOD-SCID mice engrafted with A Ϫ glucose-6-phosphate dehydrogenase (G6PD)-deficient human red blood cells (huRBCs) as described in Rochford et al. (40) following a 4-day treatment regimen at dose levels of 1.5 and 10 mg/kg/day given orally.
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